TRANSFORMATX
Live / Applied — Fourth extension granted (statement of use) (as of 24 Apr 2025)
What this means for you
Not registered yet, but its 20 Feb 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97275695
- Mark type
- Stylized text
- Filed
- 20 Feb 2022
- Published for opposition
- 11 Apr 2023
- Attorney of record
- Aaron Y. Silverstein
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for the treatment of Angelman Syndrome; Gene therapy products for the treatment of genetic disorders, namely, genetically engineered genes for the production of proteins; Gene therapy products for the treatment of Angelman Syndrome, namely, genetically engineered genes for the production of proteins
- Class 042 — Scientific and technological services: Research and development in the pharmaceutical, gene therapy, and biotechnology fields
Owner
- Transformatx Biotherapeutics LLC, Middleton, MA, US
- Transformatx Biotherapeutics LLC, Lexington, MA, US
Prosecution history
- 04 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 25 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Apr 2025 — SOU EXTENSION 4 GRANTED
- 24 Apr 2025 — SOU EXTENSION 4 FILED
- 24 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Nov 2024 — SOU EXTENSION 3 GRANTED
- 20 Nov 2024 — SOU EXTENSION 3 FILED
- 20 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 10 Apr 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Apr 2024 — SOU EXTENSION 2 GRANTED
- 09 Apr 2024 — SOU EXTENSION 2 FILED
- 09 Apr 2024 — SOU TEAS EXTENSION RECEIVED
- 15 Nov 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Nov 2023 — SOU EXTENSION 1 GRANTED